ArticleCancer immunology, immunotherapy : CII2018
Antitumor in situ vaccination effect of TNFα and IL-12 plasmid DNA electrotransfer in a murine melanoma model.
Article in Cancer immunology, immunotherapy : CII, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 33 citations in OpenAlex.
- Intratumoral Immunotherapy with Cowpea Mosaic Virus and Interleukin-12 Eliminates Established Treated Tumors and Generates Robust Systemic Immunity to Suppress the Growth of Untreated Metastatic Tumors.Molecular pharmaceutics · 2025Article
- A virus based vaccine combined with IL12 gene therapy eradicates aggressive melanoma.Scientific reports · 2025Article
- Antitumor Efficacy of Interleukin 12-Transfected Mesenchymal Stem Cells in B16-F10 Mouse Melanoma Tumor Model.Pharmaceutics · 2025Article
- Cytokine-armed pyroptosis induces antitumor immunity against diverse types of tumors.Nature communications · 2024Article
- Signaling controversy and future therapeutical perspectives of targeting sphingolipid network in cancer immune editing and resistance to tumor necrosis factor-α immunotherapy.Cell communication and signaling : CCS · 2024Review
- Immunospot Assessment of T-Cell Responses in Preclinical Tumor Models with Undefined Target Antigens.Methods in molecular biology (Clifton, N.J.) · 2024Article
- Gene Immunotherapy of Colon Carcinoma with IL-2 and IL-12 Using Gene Electrotransfer.International journal of molecular sciences · 2023Article
- Improving NonViral Gene Delivery Using MHz Bursts of Nanosecond Pulses and Gold Nanoparticles for Electric Field Amplification.Pharmaceutics · 2023Article
- Tumor Radiosensitization by Gene Electrotransfer-Mediated Double Targeting of Tumor Vasculature.International journal of molecular sciences · 2023Article
- Antitumor Activities of Interleukin-12 in Melanoma.Cancers · 2022Review
- Plasmid DNA for Therapeutic Applications in Cancer.Pharmaceutics · 2022Review
- 4-1BBL as a Mediator of Cross-Talk between Innate, Adaptive, and Regulatory Immunity against Cancer.International journal of molecular sciences · 2021Review
- Electrochemotherapy in the Treatment of Head and Neck Cancer: Current Conditions and Future Directions.Cancers · 2021Review
- Article
- Electroporation as the Immunotherapy Strategy for Cancer in Veterinary Medicine: State of the Art in Latin America.Vaccines · 2020Review
- Article
- Gene Therapy in Cancer Treatment: Why Go Nano?Pharmaceutics · 2020Review
- Article
- Immunology of IL-12: An update on functional activities and implications for disease.EXCLI journal · 2020Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Gene electrotransfer (GET) is one of the most efficient non-viral gene therapy approaches for the localized transfer of multiple genes into tumors in vivo; therefore, it is especially promising for delivering different cytokines that are toxic if administered systemically. In this study, we used concomitant intratumoral GET of two cytokines: tumor necrosis factor alpha (TNFα), a potent cytotoxic cytokine to induce in situ vaccination, and interleukin 12 (IL-12), an immunostimulatory cytokine to boost the primed local immune response into a systemic one. After performing GET in murine melanoma tumors, both TNFα and IL-12 mRNA levels were significantly increased, which resulted in a pronounced delay in tumor growth of 27 days and a prolonged survival time of mice. An antitumor immune response was confirmed by extensive infiltration of immune cells in the tumor site, and expansion of the effector immune cells in the sentinel lymph nodes. Furthermore, the effect of in situ vaccination was indicated by the presence of vitiligo localized to the treatment area and resistance of the mice to secondary challenge with tumor cells. Intratumoral GET of two cytokines, one for in situ vaccination and one for an immune boost, proved feasible and effective in eliciting a potent and durable antitumor response; therefore, further studies of this approach are warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.